Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae–Producing KPC-31, a D179Y Variant of KPC-3-Reference-Cited by-同舟云学术

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae–Producing KPC-31, a D179Y Variant of KPC-3

Published:2021-03-20 Issue:6 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Tiseo Giusy¹,Falcone Marco¹,Leonildi Alessandro²,Giordano Cesira²,Barnini Simona²,Arcari Gabriele³,Carattoli Alessandra³,Menichetti Francesco¹

Affiliation:

1. Infectious Diseases Clinic, Department of Clinical and Experimental Medicine, Azienda Universitaria Ospedaliera Pisana, University of Pisa, Pisa, Italy

2. Microbiology Unit, Azienda Universitaria Ospedaliera Pisana, Pisa, Italy

3. Department of Molecular Medicine, “Sapienza” University of Rome, Rome, Italy

Abstract

Abstract A 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)–producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab141/36649030/ofab141.pdf

Reference23 articles.

1. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae;Falcone;Clin Microbiol Infect,2016

2. Spotlight on ceftazidime/avibactam: a new option for MDR gram-negative infections;Falcone;J Antimicrob Chemother,2016

3. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae;Falcone;Crit Care,2020

4. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study;Karaiskos;J Antimicrob Chemother,2021

5. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa);Tamma;Clin Infect Dis,2021

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat;Microbiological Research;2024-11

2. Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance;International Journal of Antimicrobial Agents;2024-09

3. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases;International Journal of Antimicrobial Agents;2024-07

4. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis;Emerging Microbes & Infections;2024-06-04

5. Emergence of ceftazidime-avibactam resistance in blaKPC-33-harbouring ST11 Klebsiella pneumoniae in a paediatric patient;International Journal of Antimicrobial Agents;2024-06